Skip to main content
Top
Published in: BMC Women's Health 1/2005

Open Access 01-12-2005 | Research article

Correlation of breast cancer risk factors with HER-2/neu protein overexpression according to menopausal and estrogen receptor status

Authors: Nikos Tsakountakis, Elias Sanidas, Efstathios Stathopoulos, Maria Kafousi, Nektaria Anogiannaki, Vasilis Georgoulias, Dimitris D Tsiftsis

Published in: BMC Women's Health | Issue 1/2005

Login to get access

Abstract

Background

Several researchers have claimed that classification of tumours on the basis of HER-2/neu overexpression or amplification may define a subset of breast cancer in which the net effect of a risk factor could be rather more obvious and its impact on breast cancer development more clear. We decided to investigate, in a group of patients from a geographical area with a low incidence of breast cancer, whether HER-2/neu positive tumours are correlated with established or suspected risk factors for breast cancer and thus to identify distinct subgroups of high risk women.

Methods

This study analysed data from patients who attended the Breast Unit at the University Hospital of Heraklion, Crete, Greece between 1996 and 2002. 384 women with primary invasive breast cancer were compared with 566 screened women who were referred to the Unit and had not developed breast neoplasm by the time the data were analysed. Risk factor data were obtained from each subject by personal interviews using a structured questionnaire. The detection and scoring of the HER-2/neu protein, estrogen and progesterone receptor expression were performed using immunochemistry. Odds ratios and 95% confidence intervals were determined by chi-square test and logistic regression analysis. Case-case odds ratios were calculated in order to measure the risk heterogeneity between HER-2/neu+ and HER-2/neu-tumours. Separate analyses were performed for premenopausal and postmenopausal women and according to estrogen receptor status.

Results

In multivariate analysis without HER-2/neu stratification, an increased breast cancer risk was associated with only four of the factors examined: use of oral contraceptives (OR = 4.40, 95%C.I: 1.46–13.28), use of HRT (OR = 7.34, 95%C.I: 2.03–26.53), an age at first full pregnancy more than 23 years (OR = 1.91, 95%C.I: 1.29–2.83) and body mass index more than 29 kg/m2 (OR = 3.13, 95%C.I: 2.02–4.84). Additionally, a history of abortion or miscarriage (OR = 0.56, 95%C.I: 0.38–0.82) was correlated with a decreased risk of breast cancer. In the case to case comparison only BMI >29 kg/m2 revealed a relative connection that was stronger with positive than with negative HER-2/neu tumours (ratio of OR's = 2.23, 95%C.I: 1.20–4.15, p = 0.011). This may indicate evidence of heterogeneity of a rather significant degree for this factor. In the ER negative group an age at first full pregnancy >23 years and a BMI >29 kg/m2 were associated with an increased risk in both HER-2/neu groups, but the association was significantly stronger for the latter factor in the positive HER-2/neu tumours (ratio of OR's = 2.46, 95%CI: 0.97–6.21).

Conclusions

Our study did not confirm that the established or putative hormonal breast cancer risk factors differ regarding their relations with HER-2/neu+ versus HER-2/neu-breast tumours, with the exception of increased BMI. Further innovative studies with larger sample sizes are needed to examine how the status of these potentially modifiable breast cancer risk factors interacts with biological markers such as HER-2/neu oncoprotein.
Literature
1.
go back to reference Callahan R: Genetic alterations in primary breast cancer. Breast Cancer Res Treat. 1989, 13: 191-203.CrossRefPubMed Callahan R: Genetic alterations in primary breast cancer. Breast Cancer Res Treat. 1989, 13: 191-203.CrossRefPubMed
2.
go back to reference Ciocca DR, Fujimura FK, Tandon AK, Clark GM, Mark C, Lee-Chen GJ., Pouns GW, Vendely P, Owens MA, Pandian MR: Correlation of HER-2/neu amplification with expression and with other prognostic factors in 1103 breast cancers. J Natl Cancer Inst. 1992, 84: 1279-1282.CrossRefPubMed Ciocca DR, Fujimura FK, Tandon AK, Clark GM, Mark C, Lee-Chen GJ., Pouns GW, Vendely P, Owens MA, Pandian MR: Correlation of HER-2/neu amplification with expression and with other prognostic factors in 1103 breast cancers. J Natl Cancer Inst. 1992, 84: 1279-1282.CrossRefPubMed
3.
go back to reference Treurniet HF, Rookus MA, Peterse HL, Hart AA, van Leeuwen FE: Differences in breast cancer risk factors to neu (c-erbB2) protein overexpression of the breast tumor. Cancer Res. 1992, 52: 2344-2345.PubMed Treurniet HF, Rookus MA, Peterse HL, Hart AA, van Leeuwen FE: Differences in breast cancer risk factors to neu (c-erbB2) protein overexpression of the breast tumor. Cancer Res. 1992, 52: 2344-2345.PubMed
4.
go back to reference Isola JL, Chu S, DeVries K, Matsumura K, Chew K, Ljung BM, Waldman FM: Genetic Alterations in ERBB2-amplified Breast Carcinomas. Clin Cancer Res. 1999, 5: 4140-4145.PubMed Isola JL, Chu S, DeVries K, Matsumura K, Chew K, Ljung BM, Waldman FM: Genetic Alterations in ERBB2-amplified Breast Carcinomas. Clin Cancer Res. 1999, 5: 4140-4145.PubMed
5.
go back to reference Rosen PP, Lesser ML, Arroyo CD, Cranor M, Borgen P, Norton L: Immunohistochemical detection of HER2/neu in patients with auxiliary lymph node negative breast carcinoma. Cancer. 1995, 75: 1320-1326.CrossRefPubMed Rosen PP, Lesser ML, Arroyo CD, Cranor M, Borgen P, Norton L: Immunohistochemical detection of HER2/neu in patients with auxiliary lymph node negative breast carcinoma. Cancer. 1995, 75: 1320-1326.CrossRefPubMed
6.
go back to reference De Potter CR: The neu-oncogene: more than a prognostic indicator?. Hum Pathol. 1994, 25: 1264-1268. 10.1016/0046-8177(94)90083-3.CrossRefPubMed De Potter CR: The neu-oncogene: more than a prognostic indicator?. Hum Pathol. 1994, 25: 1264-1268. 10.1016/0046-8177(94)90083-3.CrossRefPubMed
7.
go back to reference Olsson H, Borg A, Ferno M, Ranstam J, Sirgurdsson H: Her-2/neu and INT2 proto-oncogene amplification in malignant breast tumors in relation to reproductive factors and exposure to exogenous hormones. J Natl Cancer Inst. 1991, 83: 1483-1487.CrossRefPubMed Olsson H, Borg A, Ferno M, Ranstam J, Sirgurdsson H: Her-2/neu and INT2 proto-oncogene amplification in malignant breast tumors in relation to reproductive factors and exposure to exogenous hormones. J Natl Cancer Inst. 1991, 83: 1483-1487.CrossRefPubMed
8.
go back to reference Gammon MD, Hibshoosh H, Terry MB, Bose S, Schoenberg JB, Brinton LA, Bernstein JL, Thompson WD: Oral contraceptive use and other risk factors in relation to HER-2/neu overexpression in breast cancer among young women. Cancer Epidemiol Biomarkers Prev. 1999, 8: 413-419.PubMed Gammon MD, Hibshoosh H, Terry MB, Bose S, Schoenberg JB, Brinton LA, Bernstein JL, Thompson WD: Oral contraceptive use and other risk factors in relation to HER-2/neu overexpression in breast cancer among young women. Cancer Epidemiol Biomarkers Prev. 1999, 8: 413-419.PubMed
9.
go back to reference Huang WY, Newman B, Millikan RC, Conway K, Hulka BS, Schell MJ, Liu ET: Risk of breast cancer according to the status of HER-2/neu oncogene amplification. Cancer Epidemiol Biomarkers Prev. 2000, 9: 65-71.PubMed Huang WY, Newman B, Millikan RC, Conway K, Hulka BS, Schell MJ, Liu ET: Risk of breast cancer according to the status of HER-2/neu oncogene amplification. Cancer Epidemiol Biomarkers Prev. 2000, 9: 65-71.PubMed
10.
go back to reference Jukkola A, Bloigu R, Soini Y, Savolainen ER, Holli K, Blanco G: c-erbB-2 Positivity is a factor for poor prognosis in breast cancer and poor response to hormonal or chemotherapy treatment in advanced disease. Eur J Cancer. 2001, 37: 347-354. 10.1016/S0959-8049(00)00395-6.CrossRefPubMed Jukkola A, Bloigu R, Soini Y, Savolainen ER, Holli K, Blanco G: c-erbB-2 Positivity is a factor for poor prognosis in breast cancer and poor response to hormonal or chemotherapy treatment in advanced disease. Eur J Cancer. 2001, 37: 347-354. 10.1016/S0959-8049(00)00395-6.CrossRefPubMed
11.
go back to reference Murphy LC, Watson P: Steroid receptors in human breast tumorigenesis and breast cancer progression. Biomed Pharmacother. 2002, 56: 65-77. 10.1016/S0753-3322(01)00157-3.CrossRefPubMed Murphy LC, Watson P: Steroid receptors in human breast tumorigenesis and breast cancer progression. Biomed Pharmacother. 2002, 56: 65-77. 10.1016/S0753-3322(01)00157-3.CrossRefPubMed
12.
go back to reference Liu ET, Thor A, He M, Barcos M, Ljung BM, Benz C: The HER2 (c-erbB-2) oncogene is frequently amplified in in situ carcinomas of the breast. Oncogene. 1992, 5: 1027-1032. Liu ET, Thor A, He M, Barcos M, Ljung BM, Benz C: The HER2 (c-erbB-2) oncogene is frequently amplified in in situ carcinomas of the breast. Oncogene. 1992, 5: 1027-1032.
13.
go back to reference Liu ET: Oncogenes, breast cancer, and chemoprevention. J Cell Biochem. 1993, 17G: 161-166.CrossRef Liu ET: Oncogenes, breast cancer, and chemoprevention. J Cell Biochem. 1993, 17G: 161-166.CrossRef
14.
go back to reference DAKO A/S, Glostrup DK-2600 Denmark, code # K. 5204, 2 DAKO A/S, Glostrup DK-2600 Denmark, code # K. 5204, 2
15.
go back to reference Begg CB, Zhang ZF: Statistical analysis of molecular epidemiology studies employing case-series. Cancer Epidemiol Biomarkers Prev. 1994, 3: 173-175.PubMed Begg CB, Zhang ZF: Statistical analysis of molecular epidemiology studies employing case-series. Cancer Epidemiol Biomarkers Prev. 1994, 3: 173-175.PubMed
16.
go back to reference Vlachonikolis IG†, Aletra TJ, Georgoulias V: Incidence of breast cancer on Crete, 1994–1995. Eur J Cancer. 2002, 38: 574-577. 10.1016/S0959-8049(01)00401-4.CrossRefPubMed Vlachonikolis IG†, Aletra TJ, Georgoulias V: Incidence of breast cancer on Crete, 1994–1995. Eur J Cancer. 2002, 38: 574-577. 10.1016/S0959-8049(01)00401-4.CrossRefPubMed
17.
go back to reference Matsuda S, Kadowaki Y, Ichino M, Akiyama T, Toyoshima K, Yamamoto T: 17b-Estradiol mimics ligand activity of the c-erb B2 proto-oncogene product. Proc Natl Acad Sci. 1993, 90: 10803-10807.CrossRefPubMedPubMedCentral Matsuda S, Kadowaki Y, Ichino M, Akiyama T, Toyoshima K, Yamamoto T: 17b-Estradiol mimics ligand activity of the c-erb B2 proto-oncogene product. Proc Natl Acad Sci. 1993, 90: 10803-10807.CrossRefPubMedPubMedCentral
18.
go back to reference De Bortoli M, Maggiora P, Capello D, Antoniotti S, Saviozzi S, Sapei ML, Dati C: Hormonal control of growth factor receptor expression. Ann N Y Acad Sci. 1996, 784: 336-348.CrossRefPubMed De Bortoli M, Maggiora P, Capello D, Antoniotti S, Saviozzi S, Sapei ML, Dati C: Hormonal control of growth factor receptor expression. Ann N Y Acad Sci. 1996, 784: 336-348.CrossRefPubMed
19.
go back to reference Cauley JA, Gutai JP, Kuller LH, LeDonne D, Powell JG: The epidemiology of serum sex hormones in postmenopausal women. Am J Epidem. 129 (6): 1120-1131. Cauley JA, Gutai JP, Kuller LH, LeDonne D, Powell JG: The epidemiology of serum sex hormones in postmenopausal women. Am J Epidem. 129 (6): 1120-1131.
20.
go back to reference Bernstein L: Epidemiology of endocrine-related risk factors for breast cancer. J Mammary Gland Biol Neoplasia. 2002, 1: 3-15. 10.1023/A:1015714305420.CrossRef Bernstein L: Epidemiology of endocrine-related risk factors for breast cancer. J Mammary Gland Biol Neoplasia. 2002, 1: 3-15. 10.1023/A:1015714305420.CrossRef
21.
go back to reference Lippman ME, Dickson RB: Mitogenic regulation of normal and malignant breast epithelium. Yale J Biol Med. 1989, 62: 459-480.PubMedPubMedCentral Lippman ME, Dickson RB: Mitogenic regulation of normal and malignant breast epithelium. Yale J Biol Med. 1989, 62: 459-480.PubMedPubMedCentral
22.
go back to reference Konecny G, Pauletti G, Pegram M, Untch M, Dandekar S, Aguilar Z, Wilson C, Rong HM, Bauerfeind I, Felber M, Wang HJ, Beryt M, Seshadri R, Hepp H, Slamon DJ: Quantitative association between her-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Ca Inst. 2003, 95 (2): 142-153.CrossRef Konecny G, Pauletti G, Pegram M, Untch M, Dandekar S, Aguilar Z, Wilson C, Rong HM, Bauerfeind I, Felber M, Wang HJ, Beryt M, Seshadri R, Hepp H, Slamon DJ: Quantitative association between her-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Ca Inst. 2003, 95 (2): 142-153.CrossRef
Metadata
Title
Correlation of breast cancer risk factors with HER-2/neu protein overexpression according to menopausal and estrogen receptor status
Authors
Nikos Tsakountakis
Elias Sanidas
Efstathios Stathopoulos
Maria Kafousi
Nektaria Anogiannaki
Vasilis Georgoulias
Dimitris D Tsiftsis
Publication date
01-12-2005
Publisher
BioMed Central
Published in
BMC Women's Health / Issue 1/2005
Electronic ISSN: 1472-6874
DOI
https://doi.org/10.1186/1472-6874-5-1

Other articles of this Issue 1/2005

BMC Women's Health 1/2005 Go to the issue